← Back to Search

Pharmacogenomic Modulator

Exercise for Statin Toxicity

N/A
Waitlist Available
Led By Daniel J Parente, MD PhD
Research Sponsored by University of Kansas Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults (aged 35-65 years)
English-speaking
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights

Study Summary

This study is evaluating whether genetic variations in proteins that metabolize/transport statins may impact the relationship between statin use and lack of benefit from exercise.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Peak oxygen consumption (VO2max)
Secondary outcome measures
Resting heart rate
Resting systolic blood pressure
Weight

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single armExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University of Kansas Medical CenterLead Sponsor
458 Previous Clinical Trials
169,067 Total Patients Enrolled
Daniel J Parente, MD PhDPrincipal InvestigatorUniversity of Kansas Medical Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Mar 2025